CHNA VS TMPO Stock Comparison

Performance

CHNA
10/100

CHNA returned -3.63% in the last 12 months. Based on SPY's performance of 12.05%, its performance is below average giving it a score of 10 of 100.

TMPO
10/100

TMPO returned -99.08% in the last 12 months. Based on SPY's performance of 6.52%, its performance is below average giving it a score of 10 of 100.

Technicals

CHNA
11/100

CHNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

TMPO
14/100

TMPO receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Volatility

CHNA
60/100

CHNA has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.

TMPO
53/100

TMPO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Analyst Price Targets

CHNA

"Analyst Price Targets" not found for CHNA

TMPO
75/100

1 analysts offer 12-month price targets for TMPO. Together, they have an average target of 0, the most optimistic target put TMPO at 0 within 12-months and the most pessimistic has TMPO at 0.

Sentiment

CHNA

"Sentiment" not found for CHNA

TMPO
74/100

TMPO had a bullish sentiment score of 73.88% across Twitter and StockTwits over the last 12 months. It had an average of 3.53 posts, 0.67 comments, and 0.33 likes per day.

Earnings

CHNA

"Earnings" not found for CHNA

TMPO
41/100

TMPO has missed earnings 2 times in the last 20 quarters.

Profit

CHNA

"Profit" not found for CHNA

TMPO
12/100

Out of the last 6 quarters, TMPO has had 1 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Loncar China BioPharma ETF Summary

Nasdaq / CHNA

The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.